Lentivirus-mediated delivery of sonic hedgehog into the striatum stimulates neuroregeneration in a rat model of Parkinson disease

Neurological Sciences

Volumn 35, Issue 12, 2014, Pages 1931-1940

  Zhang, Yi ^e   Dong, Weiren ^a   Guo, Suiqun ^e   Zhao, Shu ^a   He, Suifen ^b   Zhang, Lihua ^c   Tang, Yinjuan ^d   Wang, Haihong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Department of Laboratory Shunde Guizhou Hospital   (China)

^c FOSHAN UNIVERSITY   (China)

^d Xiangnan College   (China)

^e THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

N Terminal product of SHH; Neurogenesis; Neuroregeneration; Parkinson disease

Indexed keywords

DOPAMINE; LENTIVIRUS VECTOR; SONIC HEDGEHOG PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROPROTECTIVE AGENT; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEASIBILITY STUDY; LENTIVIRINAE; NERVE REGENERATION; NERVE STIMULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; STEREOTACTIC TREATMENT; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE VECTOR; GENETICS; METABOLISM; NERVE DEGENERATION; NERVE FIBER; PATHOLOGY; PHYSIOLOGY; ROTATION; SPRAGUE DAWLEY RAT; TIME;

ADRENERGIC AGENTS; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GLIAL FIBRILLARY ACIDIC PROTEIN; HEDGEHOG PROTEINS; LENTIVIRUS; NERVE DEGENERATION; NERVE FIBERS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84911955298     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1866-6     Document Type: Article

References (75)

1. Marsden CD (1994) Parkinson’s disease. J Neurol Neurosurg Psychiatry 57:672–681
2. Gibb WR (1992) Neuropathology of Parkinson’s disease and related syndromes. Neurol Clin 10:361–376
3. Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272
4. Schulz JB, Falkenburger BH (2004) Neuronal pathology in Parkinson’s disease. Cell Tissue Res 318:135–147
5. Fietz MJ, Concordet JP, Barbosa R, Johnson R, Krauss S, McMahon AP, et al (1994) The hedgehog gene family in Drosophila and vertebrate development. Dev Suppl, 43–51
6. Hammerschmidt M, Brook A, McMahon AP (1997) The world according to hedgehog. Trends Genet 13:14–21
7. Perrimon N (1995) Hedgehog and beyond. Cell 80:517–520
8. Smith JC (1994) Hedgehog, the floor plate, and the zone of polarizing activity. Cell 76:193–196
9. Bumcrot DA, Takada R, McMahon AP (1995) Proteolytic processing yields two secreted forms of Sonic hedgehog. Mol Cell Biol 15:2294–2303
10. Beachy PA, Cooper MK, Young KE, von Kessler DP, Park WJ, Hall TM et al (1997) Multiple roles of cholesterol in hedgehog protein biogenesis and signaling. Cold Spring Harb Symp Quant Biol 62:191–204
11. Pepinsky RB, Zeng C, Wen D, Rayhorn P, Baker DP, Williams KP et al (1998) Identification of a palmitic acid-modified form of human Sonic hedgehog. Biol Chem 273:14037–14045
12. Briscoe J, Sussel L, Serup P, Hartigan-O’Connor D, Jessell TM, Rubenstein JL et al (1999) Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling. Nature 398:622–627
13. Ericson J, Muhr J, Jessell TM, Edlund T (1995) Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Int J Dev Biol 39:809–816
14. Gunhaga L, Jessell TM, Edlund T (2000) Sonic hedgehog signaling at gastrula stages specifies ventral telencephalic cells in the chick embryo. Development 127:3283–3293
15. Shimamura K, Rubenstein JL (1997) Inductive interactions direct early regionalization of the mouse forebrain. Development 124:2709–2718
16. Aikin RA, Ayers KL, Thetond PP (2008) The role of kinases in the hedgehog signaling pathway. EMBO Rep 9:330–336
17. McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114
18. Ruiz iAltaba A, Palma V, Dahmane N (2002) Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci 3:24–33
19. Prakash N, Wurst W (2006) Genetic networks controlling the development of midbrain dopaminergic neurons. J Physiol 572:403–410
20. Perez-Balaguer A, Puelles E, Wurst W, Martinez S (2009) Shh dependent and independent maintenance of basal midbrain. Mech Dev 126:301–313
21. Roussa E, Krieglstein K (2004) Induction and specification of midbrain dopaminergic cells: focus on SHH, FGF8, and TGF-B. Cell Tissue Res 318:23–33
22. Martí E (1995) Requirement of 19 K of Sonic hedgehog for induction of distinct ventral cell types in CNS explants. Nature 375:322–325
23. Tanabe Y, Roelink H, Jessell TM (1995) Induction of motor neurons by Sonic hedgehog is independent of floor plate. Curr Biol 5:651–658
24. Wang MZ, Jin P, Bumcrot DA, Marigo V, McMahon AP, Wang EA et al (1995) Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat Med 1:1184–1188
25. Kim TE, Lee HS, Lee YB, Hong SH, Lee YS, Ichinose H et al (2003) Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun 305:1040–1048
26. Hynes M, Porter JA, Chiang C, Chang D, Tessier-Lavigne M, Beachy PA et al (1995) Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron 15:35–44
27. Salinas PC (2003) The morphogen sonic hedgehog collaborates with netrin-1 to guide axons in the spinal cord. Trends Neurosci 26:641–643
28. Charron F, Charron F, Stein E, Jeong J, McMahon AP, Tessier-Lavigne M (2003) The morphogen sonic hedgehog is an axonal chemoattractant that collaborates with netrin-1 in midline axon guidance. Cell 113:11–23
29. Traiffort E, Charytoniuk D, Watroba L, Faure H, Sales N, Ruat M (1999) Discrete localizations of hedgehog signalling components in the developing and adult rat nervous system. Eur J Neurosci 11:3199–3214
30. Kutner RH, Zhang XY, Reiser J (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4:495–505
31. Choudhury ME, Sugimoto K, Kubo M, Nagai M, Nomoto M, Takahashi H et al (2011) A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced parkinsonism of rats. Brain Behav 1:26–43
32. Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q et al (2007) Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer’s neurodegeneration. Proc Natl Acad Sci USA 104:3591–3596
33. Grealish S, Jönsson ME, Li M, Kirik D, Björklund A, Thompson LH (2010) The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson’s disease. Brain 133:482–495
34. Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059–3087
35. Yam PT, Langlois SD, Morin S, Charron F (2009) Sonic hedgehog guides axons through a noncanonical, Src-family-kinase-dependent signaling pathway. Neuron 62:349–362
36. Hashimoto M, Ishii K, Nakamura Y, Watabe K, Kohsaka S, Akazawa C (2008) Neuroprotective effect of sonic hedgehog up-regulated in Schwann cells following sciatic nerve injury. J Neurochem 107:918–927
37. Wu CL, Chen SD, Hwang CS, Yang DI (2009) Sonic hedgehog mediates BDNF-induced neuroprotection against mitochondrial inhibitor 3-nitropropionic acid. Biochem Biophys Res Commun 385:112–117
38. Tsuboi K, Shults CW (2002) Intrastriatal Injection of sonic hedgehog reduces behavioral impairment in a rat model of parkinson’s disease. Exp Neurol 173:95–104
39. Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB (2005) Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson’s disease using adenoviral vectors increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull 68:31–41
40. Suwelack D, Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Wawrowsky K, Lowenstein PR et al (2004) Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson’s disease. Gene Ther 11:1742–1752
41. Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Suwelack D, Castro MG, Lowenstein PR (2004) Differentiation and transcription factor gene therapy in experimental Parkinson’s disease:sonic hedgehog and gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration1. Mol Ther 10:507–524
42. Martí E, Bovolenta P (2002) Sonic hedgehog in CNS development: one signal, multiple outputs. Trends Neurosci 25:89–96
43. Emborg ME, Deglon N, Leventhal L, Aebischer P, Kordower JH (2001) Viral vector-mediated gene therapy for Parkinson’s disease. Clin Neurosci Res 1:496–506
44. Bensadoun JC, Widmer HR, Zurn AD, Aebischer P (2001) Polymer encapsulated cells as a tool for drug delivery and neural transplantation in Parkinson’s disease. In: Krauss JK, Jankovic J (eds) Surgery for Parkinson’s disease and movement disorders. Lippincott Williams&Wilkins, Philadelphia, pp 245–251
45. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson’s disease. Nat Med 9:589–595
46. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12:1259–1268
47. Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R, Isacson O (2007) Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 25:411–418
48. Snyder BJ, Olanow CW (2005) Stem cell treatment for Parkinson’s disease: an update for 2005. Curr Opin Neurol 18:376–385
49. Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P (2000) Lentiviral vectors as a gene delivery system in the mouse midbrain:cellular and behavioral improvements in a 6-OHDA model of Parkinson’s disease using GDNF. Exp Neurol 164:15–24
50. Georgievska B, Kirik D, Björklund A (2004) Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time-and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24:6437–6445
51. Rosenblad C, Grønborg M, Hansen C, Blom N, Meyer M, Johansen J et al (2000) In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol Cell Neurosci 15:199–214
52. Kirik D, Rosenblad C, Björklund A (2000) Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12:3871–3882
53. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20:4686–4700
54. Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13:75–82
55. Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ (2000) Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886:82–98
56. Lo Bianco C, Déglon N, Pralong W, Aebischer P (2004) Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease. Neurobiol Dis 17:283–289
57. Diaz Jaime (1996) How drugs influence behavior. Prentice-Hall, Englewood Cliffs
58. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909
59. Tieu K (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med 1:a009316
60. Anastasía A, Torre L, de Erausquin GA, Mascó DH (2009) Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson’s disease. J Neurochem 109:755–765
61. Asanuma C (1992) Noradrenergic innervation of the thalamic reticular nucleus: a light and electron microscopic immunohistochemical study in rats. J Comp Neurol 319:299–311
62. Cornwall J, Phillipson OT (1988) Quantitative analysis of axonal branching using the retrograde transport of fluorescent latex microspheres. J Neurosci Methods 24:1–9
63. Schmued LC (1994) Diagonal ventral forebrain continuum has overlapping telencephalic inputs and brainstem outputs which represent loci for limbic/autonomic integration. Brain Res 667:175–191
64. Schmued L, Kyriakidis K, Heimer L (1990) In vivo anterograde and retrograde axonal transport of the fluorescent rhodamine-dextran-amine Fluoro-Ruby within the CNS. Brain Res 526:127–134
65. Schofield BR (2010) Projections from auditory cortex to midbrain cholinergic neurons that project to the inferior colliculus. Neuroscience 166:231–240
66. Kang N, Baum MJ, Cherry JA (2009) A direct main olfactory bulb projection to the ‘vomeronasal’ amygdala in female mice selectively responds to volatile pheromones from males. Eur J Neurosci 29:624–634
67. Bowyer JF, Schmued LC (2006) Fluoro-Ruby labeling prior to an amphetamine neurotoxic insult shows a definitive massive loss of dopaminergic terminals and axons in the caudate-putamen. Brain Res 1075:236–239
68. O’Rourke NA, Fraser SE (1986) Dynamic aspects of retino-tectalmap formation revealed by a vital-dyefiber-tracing technique. Dev Biol 114:265–276
69. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455
70. Rosenblad C, Kirik D, Björklund A (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 161:503–516
71. Winkler C, Sauer H, Lee CS, Björklund A (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson’s disease. J Neurosci 16:7206–7215
72. Lapchak PA, Miller PJ, Jiao S (1997) Glial cell line derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience 77:745–752
73. Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J, Baumann NA (1978) Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci 35:147–155
74. L’ Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy of Parkinson’s disease. CNS Neurol Disord Drug Targets 9:349–372
75. Khoo ML, Tao H, Meedeniya AC, Mackay-Sim A, Ma DD (2011) Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One 6:e19025